Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Shuai Xia; Jasper Fuk Woo Chan; Lijue Wang; Fanke Jiao; Kenn Ka Heng Chik; Hin Chu; Qiaoshuai Lan; Wei Xu; Qian Wang; Chao Wang; Kwok Yung Yuen; Lu Lu; Shibo Jiang

doi:10.1038/s41422-022-00617-x

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Shuai Xia, Jasper Fuk Woo Chan, Lijue Wang, Fanke Jiao, Kenn Ka Heng Chik, Hin Chu, Qiaoshuai Lan, Wei Xu, Qian Wang, Chao Wang, Kwok Yung Yuen, Lu Lu, Shibo Jiang

Research output: Contribution to journal › Letter › peer-review

33 Citations (Scopus)

Original language	English
Pages (from-to)	404-406
Number of pages	3
Journal	Cell Research
Volume	32
Issue number	4
DOIs	https://doi.org/10.1038/s41422-022-00617-x
Publication status	Published - Apr 2022
Externally published	Yes

ASJC Scopus Subject Areas

Molecular Biology
Cell Biology

Access to Document

10.1038/s41422-022-00617-x

Cite this

@article{b63e2171d9d84e74bcd65e008a09e5c8,

title = "Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant",

author = "Shuai Xia and Chan, {Jasper Fuk Woo} and Lijue Wang and Fanke Jiao and Chik, {Kenn Ka Heng} and Hin Chu and Qiaoshuai Lan and Wei Xu and Qian Wang and Chao Wang and Yuen, {Kwok Yung} and Lu Lu and Shibo Jiang",

year = "2022",

month = apr,

doi = "10.1038/s41422-022-00617-x",

language = "English",

volume = "32",

pages = "404--406",

journal = "Cell Research",

issn = "1001-0602",

number = "4",

}

TY - JOUR

T1 - Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

AU - Xia, Shuai

AU - Chan, Jasper Fuk Woo

AU - Wang, Lijue

AU - Jiao, Fanke

AU - Chik, Kenn Ka Heng

AU - Chu, Hin

AU - Lan, Qiaoshuai

AU - Xu, Wei

AU - Wang, Qian

AU - Wang, Chao

AU - Yuen, Kwok Yung

AU - Lu, Lu

AU - Jiang, Shibo

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85123795492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123795492&partnerID=8YFLogxK

U2 - 10.1038/s41422-022-00617-x

DO - 10.1038/s41422-022-00617-x

M3 - Letter

C2 - 35087243

AN - SCOPUS:85123795492

SN - 1001-0602

VL - 32

SP - 404

EP - 406

JO - Cell Research

JF - Cell Research

IS - 4

ER -

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this